3 Things You Should Know About ADCs in Early-Stage TNBC and Considerations for Implementation.
| Publicado en: | Oncology (08909091) Vol. 39; no. 10; pp. 479 - 483 |
|---|---|
| Formato: | CEU exam questions tables/charts Journal Article |
| Publicado: |
MJH Life Sciences
Nov/Dec2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=189929351&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 189929351 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 08909091 YYT jtl: Oncology (08909091) issn: 08909091 maglogo: N pubinfo: dt: Nov/Dec2025 vid: 39 iid: 10 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 189929351 189929351 189929351 189929351 ppf: 479 ppct: 4 formats: fmt: @attributes: type: P tig: atl: 3 Things You Should Know About ADCs in Early-Stage TNBC and Considerations for Implementation. aug: sug: subj: Neoplasm Staging Breast Neoplasms Drug Therapy Antibodies, Monoclonal Therapeutic Use Treatment Outcomes Education, Continuing (Credit) Drugs, Investigational Drug Toxicity Antibodies, Monoclonal Administration and Dosage Drug Approval pubtype: Academic Journal doctype: CEU exam questions tables/charts Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|